Skip to main content
Premium Trial:

Request an Annual Quote

PolyGenyx Snares $1M SBIR Help for Haplotyping

NEW YORK, June 25 -- PolyGenyx, a Worcester, Mass., haplotyping startup, announced today that it has received a $997,673 Phase II Small Business Innovative Research grant from the National Human Genome Research Institute.

The company plans to use the grant, which spans two years, on development of HaploScan, its haplotyping platform, and develop haplotyping assays for the platform that can be commercialized.

The technology, based on the Luminex 100 microbead system, requires less than one hour for users to haplotype samples that involve two-SNP or multi-SNP haplotpyes.

The company adapted the technology for the Luminex platform in a previous Phase 1 SBIR grant. HapScan can also be automated, according to PolyGenyx, using standard liquid handling robots. The company is developing software for the automation of haplotype scoring.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.